(HELX) Franklin Genomic - Ratings and Ratios

The Franklin Genomic Advancements ETF (BATS:HELX) is a non-diversified investment fund focused on companies driving innovation in genomic sciences and related biotechnology sectors. Under normal market conditions, the fund allocates at least 80% of its net assets to equity securities of firms involved in genomic advancements, primarily through common stocks. While it may explore opportunities across various economic sectors, its investments are heavily concentrated in healthcare-related industries.

As of the latest data, HELX has an average 20-day trading volume of 1,913 shares, with a last price of $28.71. Its short-term and medium-term moving averages (20-day: $29.66, 50-day: $29.82) suggest recent price fluctuations, while the 200-day SMA of $31.30 indicates a downward trend over the longer term. The Average True Range (ATR) of 0.44 reflects moderate volatility, while the funds assets under management (AUM) stand at $11.87 million.

Over the next three months, HELX is expected to face resistance near its 50-day SMA of $29.82, with potential support at its 200-day SMA of $31.30. The ATR of 0.44 suggests that price movements may remain bounded within a narrow range. Given the funds concentrated exposure to healthcare and biotechnology, its performance will likely hinge on sector-specific developments and broader market sentiment.